Ascendis Pharma A/S $ASND

Health Care · NASDAQ

Russell 1000 Denmark
$252.73
-3.23 (-1.26%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Nov 13, 2026, the first target we tracked for ASND.

Ascendis Pharma A/S (ASND) is trading down at $252.73 (-1.26%) on NASDAQ, as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

IPO: January 28, 2015 · $18.00 offering · NASDAQ

Analyst price targets on ASND

One firm's current price target on Ascendis Pharma A/S: $330 — 31% above the current $253. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateNov 13, 2026 FirmWells Fargo RatingOverweight · raises Targetat $275 · $330 +20% Horizonby Nov 2027 StatusOpen

Entry price $275, the close nearest Nov 13, 2026, when the target was reported; the target is +20% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 13, 2027.

Source Wells Fargo raises Ascendis Pharma stock price target on growth outlook Investing.com · Nov 13, 2026 · opens the publisher's site
Wells Fargo raised its price target on Ascendis Pharma (NASDAQ:ASND) to $330 from $326 while maintaining an Overweight rating on the shares.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Ascendis Pharma A/S revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
€720.1M€68.5M−€583.2MFY2016 revenue: €4.61MFY2016 net income: −€68.5M · Net margin −1487.3%'16FY2017 revenue: €1.53MFY2017 net income: −€123.9M · Net margin −8097.8%'17FY2018 revenue: €10.6MFY2018 net income: −€130.1M · Net margin −1229.5%'18FY2019 revenue: €13.4MFY2019 net income: −€218.0M · Net margin −1630.0%'19FY2020 revenue: €6.95MFY2020 net income: −€419.0M · Net margin −6025.5%'20FY2021 revenue: €7.78MFY2021 net income: −€383.6M · Net margin −4931.6%'21FY2022 revenue: €51.2MFY2022 net income: −€583.2M · Net margin −1139.6%'22FY2023 revenue: €266.7MFY2023 net income: −€481.4M · Net margin −180.5%'23FY2024 revenue: €363.6MFY2024 net income: −€378.1M · Net margin −104.0%'24FY2025 revenue: €720.1MFY2025 net income: −€228.0M · Net margin −31.7%'25−100%−50%0%50%FY2016 net margin: −1487.3% (off the scale, which stops at −100.0%)FY2017 net margin: −8097.8% (off the scale, which stops at −100.0%)FY2018 net margin: −1229.5% (off the scale, which stops at −100.0%)FY2019 net margin: −1630.0% (off the scale, which stops at −100.0%)FY2020 net margin: −6025.5% (off the scale, which stops at −100.0%)FY2021 net margin: −4931.6% (off the scale, which stops at −100.0%)FY2022 net margin: −1139.6% (off the scale, which stops at −100.0%)FY2023 net margin: −180.5% (off the scale, which stops at −100.0%)FY2024 net margin: −104.0% (off the scale, which stops at −100.0%)FY2025 net margin: −31.7%
Ascendis Pharma A/S annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue€4.61M€1.53M€10.6M€13.4M€6.95M€7.78M€51.2M€266.7M€363.6M€720.1M
Growth (year over year)−43.3%−66.8%+591.6%+26.4%−48.0%+11.9%+557.9%+421.2%+36.3%+98.0%
Gross profit———€13.4M€6.95M€4.25M€39.0M€222.3M€319.4M€625.2M
Gross margin———100.0%100.0%54.7%76.3%83.4%87.8%86.8%
Operating income−€72.9M−€111.5M−€154.8M−€226.7M−€330.6M−€451.8M−€561.8M−€455.5M−€278.8M−€136.3M
Operating margin−1583.2%−7290.3%−1462.6%−1695.1%−4755.1%−5808.6%−1097.9%−170.8%−76.7%−18.9%
Net income−€68.5M−€123.9M−€130.1M−€218.0M−€419.0M−€383.6M−€583.2M−€481.4M−€378.1M−€228.0M
Net margin−1487.3%−8097.8%−1229.5%−1630.0%−6025.5%−4931.6%−1139.6%−180.5%−104.0%−31.7%
EPS (diluted)−€2.58−€3.68−€3.17−€4.69−€8.28−€7.00−€10.40−€8.55−€6.53−€3.76
Balance sheet
Cash and equivalents€180.3M€195.4M€277.9M€598.1M€584.5M€446.3M€444.8M€392.2M€559.5M€616.0M
Total assets€190.1M€211.0M€319.0M€676.7M€979.8M€1.08B€1.09B€825.6M€1.18B€1.30B
Total liabilities€13.5M€23.8M€38.9M€79.6M€141.1M€201.3M€826.4M€971.3M€1.29B€1.47B
Shareholders' equity€176.6M€187.2M€280.1M€597.1M€838.7M€883.6M€263.3M−€145.7M−€105.7M−€162.8M
Cash flow
Operating cash flow−€60.2M−€95.1M−€138.8M−€175.9M−€271.5M−€417.6M−€495.7M−€467.4M−€306.2M€53.9M
Capital expenditure€672.0K€941.0K€2.65M€5.16M€19.9M€23.7M€14.5M€2.44M——
Free cash flow−€60.9M−€96.0M−€141.4M−€181.1M−€291.4M−€441.4M−€510.2M−€469.8M——
Share buybacks—————€21.6M€105.3M€0€0€17.4M

From Ascendis Pharma A/S's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Amounts are in Euro (EUR), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Ascendis Pharma A/S in the news

Nov 10, 2026 GlobeNewswire Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
Sep 8, 2026 GlobeNewswire Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Sep 7, 2026 GlobeNewswire Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
Aug 25, 2026 GlobeNewswire Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

Also mentions CenterPoint Energy

About Ascendis Pharma A/S

Headquarters
Hellerup, Denmark From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →

Mentioned with Ascendis Pharma A/S in recent news